Glenmark Pharmaceuticals SA, of Mumbai, India, and Shanghai-based Harbour Biomed Inc. have entered an exclusive license agreement for the greater China territory to develop, manufacture and commercialize GBR-1302, Glenmark's bispecific antibody targeting HER2 and CD3 for the treatment of HER2-positive cancers. It's Glenmark's lead immuno-oncology candidate.